MSLN Chimeric Antigen Receptor (CAR): A Comprehensive Guide and Our Service & Product Introduction

Mesothelin (MSLN) remains one of the most validated and clinically promising targets for solid tumor immunotherapy, with MSLN CAR therapy positioned to address the unmet medical need of hard-to-treat malignancies like mesothelioma, ovarian cancer, and pancreatic cancer. As the field advances toward next-generation CAR design and off-the-shelf immune cell therapies, high-quality, reliable MSLN CAR expression plasmids are critical for accelerating research and translation. RGBiotech’s comprehensive vector portfolio and custom services provide researchers with the tools needed to drive innovation, optimize CAR design, and advance MSLN-targeted immunotherapies toward clinical approval.

For custom MSLN CAR vector quotes, product catalog requests, or technical support, please reach out to us at admin@rgbiotech.com. We are dedicated to empowering your cancer immunotherapy research.

Our MSLN CAR Expression Plasmid Vector Products and Custom Services

RGBiotech offers a comprehensive range of MSLN CAR expression plasmids and tailored custom MSLN CAR vector construction services to support research. Our vectors cover different generations of CAR design and multiple delivery platforms, fully optimized for high expression efficiency, stability, and experimental flexibility for academic labs, biotech startups, and pharmaceutical companies.

Each generation of MSLN CAR vectors is engineered for distinct research objectives and therapeutic performance.
1) 1st Generation MSLN CAR: Basic backbone with anti-MSLN scFv + transmembrane domain + CD3ζ cytoplasmic signaling domain; ideal for initial target validation and in vitro cytotoxicity screening.
2) 2nd Generation MSLN CAR: Most widely used for preclinical research; includes anti-MSLN scFv + CD3ζ + one co-stimulatory domain (CD28, 4-1BB, or OX40); significantly enhances T cell activation, proliferation, and in vivo persistence.
3) 3rd Generation MSLN CAR: Dual co-stimulatory domains (e.g., CD28+4-1BB) combined with CD3ζ; boosts cytotoxicity and survival in immunosuppressive TMEs, suitable for solid tumor models.
4) 4th Generation (Armored MSLN CAR): 2nd/3rd gen backbone with transgenic cytokine secretion (IL-12, IL-15, or IL-21); remodels the TME, enhances CAR cell persistence, and activates endogenous anti-tumor immunity.
5) 5th Generation (Smart MSLN CAR): Engineered with safety switches, inducible promoters, or dual-antigen logic gating; improves tumor selectivity and clinical safety profile.

We provide MSLN CAR plasmids built on multiple vector skeletons to meet different gene delivery needs, compatible with various immune cell engineering workflows.
1) Lentiviral Vectors: Production of lentiviral particles, high transduction efficiency for both dividing and non-dividing immune cells (T cells, NK cells); stable genomic integration; ideal for stable CAR cell line generation.
2) Retroviral Vectors: Production of retroviral particles, efficient integration in dividing T cells; widely used in clinical CAR-T manufacturing workflows.
3) AAV Vectors: Production of AAV particles, non-integrating, low immunogenicity; suitable for in vivo local delivery (intraperitoneal/intratumoral) and transient expression.
4) Non-Viral Plasmid Vectors: Safe, cost-effective, and easy to amplify; designed for electroporation, lipofection, and non-viral cell engineering; no viral sequence risks.

Product Features

Product Applications

Custom MSLN CAR Plasmid Construction Service

We provide fully customized MSLN CAR vector services tailored to your unique research needs: from scFv sequence design and codon optimization to vector backbone selection, reporter gene insertion, and dual-target CAR assembly. Our team of molecular biology experts supports the entire construction process, delivering sequence-verified, high-quality plasmids with comprehensive QC reports, supporting your entire research pipeline from early discovery to translational development.

Introduction of MSLN

Mesothelin (MSLN) is a protein-coding gene located on the short arm of human chromosome 16p13.3 (NCBI Gene ID: 10232), initially identified and named for its specific expression in normal mesothelial cells. The gene encodes a 69 kDa precursor preproprotein that undergoes proteolytic cleavage by the furin endoprotease during post-translational processing, generating two functional products: a 31 kDa megakaryocyte-potentiating factor (MPF) secreted into the extracellular environment, and a mature 40 kDa glycosylphosphatidylinositol (GPI)-anchored membrane protein (the canonical mesothelin). Alternative splicing of the MSLN gene generates multiple transcript variants, with the dominant isoform encoding the full-length membrane-bound protein widely studied in cancer research. Notably, MSLN expression is tightly silenced in most normal adult tissues post-development, but becomes drastically dysregulated in a broad range of malignant tumors, making it a clinically valuable tumor-associated antigen (TAA).

Mature membrane-bound MSLN is a highly stable GPI-anchored cell surface glycoprotein with a core sequence of 303 amino acids, characterized by distinct structural domains that support its biological and pathological functions. 1) N-terminal signal peptide: Guides the nascent protein through the endoplasmic reticulum and Golgi apparatus for post-translational modification and membrane targeting. 2) Extracellular functional domain: Contains multiple alpha-helix regions and N-linked glycosylation sites, which mediate specific binding to its natural ligand MUC16 (CA125) and promote cell-cell adhesion; this domain is the primary target epitope for MSLN-targeted therapeutic antibodies and CAR constructs. 3) C-terminal GPI anchor: Tethers the protein to the outer leaflet of the plasma membrane without a cytoplasmic signaling domain, meaning MSLN exerts biological effects via co-receptor interactions and downstream signaling cascades rather than direct intracellular signaling.

Under normal physiological conditions, MSLN is largely dispensable for organismal development and reproduction-MSLN knockout mice exhibit normal viability, fertility, and tissue development, with no overt phenotypic defects. Pathologically, MSLN overexpression drives multiple hallmarks of cancer progression. 1) Tumor cell adhesion & metastasis: Mediates binding between tumor cells and peritoneal mesothelial cells, facilitating peritoneal implantation and distant metastasis of abdominal and thoracic tumors. 2) Chemotherapy resistance: Upregulates anti-apoptotic signaling pathways, reducing tumor cell sensitivity to conventional chemotherapeutic agents (e.g., paclitaxel, gemcitabine) and contributing to treatment failure. 3) Immune evasion: Modulates the tumor microenvironment (TME) to suppress anti-tumor immune cell infiltration and activation, protecting tumor cells from immune clearance. 4) Cell proliferation & survival: Promotes tumor cell proliferation and inhibits apoptosis, supporting sustained tumor growth and cancer stem cell maintenance.

MSLN exhibits a highly restricted expression pattern in normal human tissues, limited to low-level expression on the surface of mesothelial cells lining the pleura, peritoneum, and pericardium. All other major vital organs (heart, liver, kidney, brain, digestive tract) show negligible to no MSLN expression. In stark contrast, MSLN is overexpressed in 80–100% of several aggressive solid tumors, with minimal heterogeneity in target expression within tumor tissue, making it an ideal target for targeted immunotherapy with low risk of on-target off-tumor toxicity.

MSLN overexpression is most strongly linked to aggressive solid tumors, the core indication for MSLN CAR therapy. 1) Pleural mesothelioma: Nearly 100% of epithelioid mesothelioma cases show high MSLN expression, a rare and highly lethal thoracic tumor linked to asbestos exposure. 2) Ovarian epithelial cancer: High expression in most high-grade serous ovarian cancers, the most common and lethal subtype of ovarian cancer. 3) Pancreatic ductal adenocarcinoma (PDAC): Overexpressed in ~80–90% of cases, a notoriously treatment-resistant solid tumor with poor 5-year survival. 4) Other solid tumors: Non-small cell lung cancer (adenocarcinoma), cholangiocarcinoma, gastric cancer, colorectal cancer, and endometrial cancer. Additionally, abnormal MSLN expression is associated with certain fibrotic diseases (e.g., pulmonary fibrosis, peritoneal fibrosis) and chronic inflammatory conditions linked to tissue remodeling.

Introduction of MSLN Chimeric Antigen Receptor (CAR)

Mesothelin Chimeric Antigen Receptor (MSLN CAR) is a genetically engineered synthetic receptor designed to redirect the cytotoxic activity of immune effector cells (primarily T cells, NK cells, or macrophages) to specifically recognize and eliminate MSLN-positive tumor cells. MSLN CAR constructs bypass the limitations of natural T cell receptor (TCR) recognition, enabling MHC-independent targeting of MSLN-expressing tumor cells. A typical MSLN CAR consists of three core components: an MSLN-specific single-chain variable fragment (scFv) derived from a high-affinity anti-MSLN antibody (extracellular antigen-binding domain), a hydrophobic transmembrane domain, and an intracellular signaling domain that triggers immune cell activation and cytotoxicity.

Key Research & Clinical Achievements

MSLN CAR therapy has emerged as one of the most promising immunotherapeutic strategies for hard-to-treat solid tumors, with robust preclinical and clinical evidence supporting its efficacy.
1) Preclinical efficacy: Multiple in vitro and in vivo studies confirm that MSLN CAR-T/NK cells exert potent, specific cytotoxicity against MSLN-positive tumor cell lines and patient-derived xenografts (PDX), inducing significant tumor regression and prolonging survival in models of mesothelioma, ovarian cancer, and pancreatic cancer.
2) Clinical trial breakthroughs: Early-phase clinical trials (Phase I/II) demonstrate manageable safety profiles and promising anti-tumor activity in relapsed/refractory solid tumors, with durable partial responses (PR) and stable disease (SD) observed in heavily pre-treated patients.
3) Combination therapy synergy: MSLN CAR therapy combined with immune checkpoint inhibitors (anti-PD-1/PD-L1), chemotherapy, oncolytic viruses, or small-molecule targeted drugs enhances tumor infiltration and cytotoxicity, overcoming TME-mediated immunosuppression.
4) Universal immune cell platforms: MSLN CAR-NK cells (allogeneic, off-the-shelf) and CAR-macrophages show comparable efficacy to CAR-T with lower immunogenicity and reduced risk of cytokine release syndrome (CRS).

Approved MSLN-Targeted Drugs & Clinical-Stage Agents

As of 2026, no MSLN CAR-T cell therapy has received full global regulatory approval (FDA/EMA/NMPA); all MSLN CAR constructs remain in active clinical development.
1) Several MSLN-targeted antibody-drug conjugates (ADCs) have advanced to late-phase clinical trials and received breakthrough therapy designation for advanced solid tumors.
2) Dozens of MSLN CAR-T, MSLN CAR-NK, and dual-target MSLN CAR clinical trials are registered globally (ClinicalTrials.gov), focusing on mesothelioma, ovarian cancer, and pancreatic cancer.
3) Next-generation logic-gated and tumor microenvironment-responsive MSLN CAR variants are in early clinical evaluation to improve safety and tumor selectivity.

Current Research Hotspots

Research Challenges & Limitations

References

Contact Us